|
Vemurafenib Clinical Trials
7 actively recruiting trials across 3 locations
Also known as: BRAF (V600E) kinase inhibitor RO5185426, BRAF(V600E) Kinase Inhibitor RO5185426, PLX-4032, PLX4032, RG 7204 +4 more
Pipeline
Phase 2: 4Phase 1/2: 1Phase 2/3: 1
Top Sponsors
- University of Louisville1
- Seoul National University Bundang Hospital1
- Memorial Sloan Kettering Cancer Center1
- Helsinki University Central Hospital1
- Genentech, Inc.1
Indications
- Cancer7
- Haematological Malignancy2
- Melanoma2
- Solid Tumor2
- Lung Cancer2
Other3 trials
Duarte, California2 trials
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
City of Hope Comprehensive Cancer Center
Phase 2
Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation
City of Hope Medical Center
Phase 2
Louisville, Kentucky1 trial
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
James Graham Brown Cancer Center-University of Louisville
Phase 1/2
Boston, Massachusetts1 trial
A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)
Dana Farber Cancer Institute
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.